Management of malignant hyperthermia: diagnosis and treatment

Daniel Schneiderbanger
Stephan Johannsen
Norbert Roewer
Frank Schuster
Department of Anaesthesia and Critical Care, University of Wuerzburg, Wuerzburg, Germany

Correspondence: Frank Schuster
Department of Anaesthesia and Critical Care, University of Wuerzburg, Oberduerrbacher Strasse 6, D-97080 Wuerzburg, Germany
Tel +49 931 2013 0038
Fax +49 931 2013 0039
Email schuster_f@ukw.de

Abstract: Malignant hyperthermia is a potentially lethal inherited disorder characterized by disturbance of calcium homeostasis in skeletal muscle. Volatile anesthetics and/or the depolarizing muscle relaxant succinylcholine may induce this hypermetabolic muscular syndrome due to uncontrolled sarcoplasmic calcium release via functionally altered calcium release receptors, resulting in hypoxemia, hypercapnia, tachycardia, muscular rigidity, acidosis, hyperkalemia, and hyperthermia in susceptible individuals. Since the clinical presentation of malignant hyperthermia is highly variable, survival of affected patients depends largely on early recognition of the symptoms characteristic of malignant hyperthermia, and immediate action on the part of the attending anesthesiologist. Clinical symptoms of malignant hyperthermia, diagnostic criteria, and current therapeutic guidelines, as well as adequate management of anesthesia in patients susceptible to malignant hyperthermia, are discussed in this review.

Keywords: malignant hyperthermia, volatile anesthetics, succinylcholine, in vitro contracture test, genetics

Introduction
Malignant hyperthermia (MH) is a rare, but life-threatening, autosomal-dominant inherited disorder that may lead to metabolic crisis of skeletal muscle in susceptible individuals following exposure to triggering agents, such as volatile anesthetics or depolarizing muscle relaxants. Functionally altered calcium release channels cause dysfunction of intracellular calcium homeostasis and uncontrolled calcium release from the sarcoplasmic reticulum, which may lead rapidly to a fatal hypermetabolic state known as MH crisis. Interestingly, in everyday life, most MH-susceptible (MHS) individuals do not suffer from muscle symptoms. Nevertheless, MH is still a relevant complication and every anesthesiologist must recognize the symptoms of an MH episode and start appropriate treatment without delay.

History
From the beginning of the 20th century, there have been numerous case reports of anesthesia-associated deaths related to perioperative hyperthermia. However, it was not until 1960, when Denborough et al defined MH as an independent syndrome, that the link between deaths attributed to general anesthesia and a genetic predisposition was postulated. In 1975, with the introduction of dantrolene as a specific ryanodine receptor antagonist, a causative treatment became available and the mortality rate for acute MH crisis decreased from approximately 70%–80% to about 5%. Based on in vitro
detection of halothane-induced and caffeine-induced contrac-
tures in skeletal muscle specimens from MHS individuals,
the first diagnostic procedure was developed to distinguish
between MHS and MH-non-susceptible (MHN) patients
independently of a previous symptomatic MH event.8,9

Following these observations, a standardized protocol for in
vitro contracture testing was published by the European Malign-
ant Hyperthermia Group in 1984, and a modified protocol was
introduced by the North American Malignant Hyperthermia
Group 3 years later.10,11 After MH-associated mutations in
the ryanodine receptor gene were identified, guidelines for
genetic testing allowing diagnosis of MH susceptibility in
selected patients were published by the European Malignant
Hyperthermia Group in 2001 and are still under development
as more causative mutations become apparent.12

Epidemiology
MH occurs worldwide in all races.7 Children and young adults
are mostly affected, with a significant male preponderance.7,13,14 According to a prevalence study in
New York State between 2001 and 2005, the estimated
prevalence of MH was 2.5–4.5 times higher in males than
in females.15 Since many MHS individuals experience no
symptoms in daily life, the true incidence of MH remains
unknown. The predicted genetic prevalence is reported to be
one in 2,000, while the incidence of clinical MH episodes
varies regionally from one in 5,000 to one in 100,000.7,16,17
In contrast with fulminant episodes, abortive courses might
occur more frequently, but are difficult to diagnose due to
their mild symptoms.18

Recent developments in anesthesiology seem to have led
to a decrease in the risk of severe MH crisis over the last few
years. Halothane, a potent MH-triggering agent, is no longer
used in western countries.19 Compared with halothane,
the onset of MH is delayed with the volatile anesthetics cur-
cently in use,20,21 and is more likely to be abortive MH with
attenuated symptoms. Further, the recommended indica-
tions for succinylcholine, another possible triggering agent,
have been gradually restricted by international anesthe-
sia societies.18,22

Pathophysiology
During excitation–contraction coupling, acetylcholine
evokes an action potential at the neuromuscular endplate.
This action potential is propagated to the transverse tubule,
causings displacement of the charge at the dihydropyridine
receptor. A conformational change at the voltage-gated
dihydropyridine receptor is directly transmitted to the
ryanodine receptor subtype 1 (RYR1) at the sarcoplasmic
reticulum, which responds by opening. RYR1, a large ion
channel, facilitates release of calcium from the sarcoplasmic reticulum into the cytosol, leading to muscle contraction by
initiating cross-linking of myofilaments. Active reuptake of
calcium into the sarcoplasmic reticulum via an adenosine
triphosphate-dependent calcium pump terminates the muscle
contraction.23

In an MH crisis, the triggering agent induces prolonged
opening of functionally altered ryanodine receptors, resulting
in uncontrolled release of calcium from the sarcoplasmic retic-
ulum and ongoing muscle activation presenting as rigidity.24–27
Additionally, constant activation of aerobic and anaerobic
metabolism results in increased oxygen consumption, leading
to hypoxia, progressive lactate acidosis, excessive production
of CO2, and increased body temperature (Figure 1).

Calcium reuptake into the sarcoplasmic reticulum and
sustained muscle contraction consume large amounts of
adenosine triphosphate. Depletion of cellular adenosine
triphosphate stores leads to protracted muscular rigidity and
finally to rhabdomyolysis, when breakdown of mem-
brane integrity results in release of the contents of cells (eg,
potassium, creatine phosphokinase, myoglobin) into the
circulation.7,28

Genetics
Three mammalian isoforms of the ryanodine receptor are
known: RYR1, predominant in skeletal muscle; RYR2,
primarily expressed in heart muscle; and RYR3, found
in the central nervous system and in skeletal and smooth
muscle.29–31 From the early 1990s, mutations in the RYR1
gene on chromosome 19q13.1 have been associated with a
predisposition to MH.32 More than 300 RYR1 variants have
been identified to date, but only 31 mutations have been
functionally tested in intracellular calcium-releasing stud-
ies and confirmed to be causative of MH according to the
molecular genetics guidelines of the European Malignant
Hyperthermia Group.33,34 Interestingly, a causative muta-
tion in RYR1 was detected in only about 50% of MHS
patients.36–38 The RYR1 gene is not solely responsible for
susceptibility to MH in all affected individuals. Another
gene locus has been identified in MHS patients on chromo-
some 1q32, encoding the α1 subunit of the voltage-gated
dihydropyridine receptor.39,40

Agents triggering MH
It is well accepted that all volatile halogenated inhalational
anesthetics (eg, halothane, enflurane, isoflurane, desflurane,
sevoflurane) have the potential to induce an MH crisis in MHS individuals. Studies in MHS pigs and in vitro studies indicate that nitrous oxide and the noble gas xenon do not trigger MH. Further, it is important to mention that exposure to volatile anesthetics does not inevitably lead to MH. Several patients have reported a number of uneventful anesthesias before an MH episode occurred. Triggering MH might be in part a dose-dependent phenomenon, which is consistent with the interindividual variability and graded incremental contracture response of MHS muscle during the in vitro contracture test. The trigger potency of the depolarizing muscle relaxant succinylcholine has been unclear for a long time, although there is no doubt that this substance enhances an MH reaction and decreases the likelihood of survival in

Figure 1 Pathophysiologic changes during a malignant hyperthermia crisis.

Abbreviations: Ca\(^{2+}\), calcium; DHP receptor, dihydropyridine receptor; MH, malignant hyperthermia; RYR1, ryanodine receptor subtype 1.
patients who receive a combination of succinylcholine and a volatile anesthetic, compared with a volatile anesthetic alone.6,20 However, two recent retrospective studies reported a number of cases in which succinylcholine was the sole trigger of an MH event.19,46 Over the years, several drugs have been suspected to cause MH. However, in vitro and in vivo studies of serotonergic drugs, phosphodiesterase type III inhibitors, and ondansetron have not provided convincing evidence of their propensity to act as MH triggers.20,47

Interestingly, there are some reports of fulminant MH-like episodes occurring in the absence of anesthetic agents.48,49 MH episodes in the wake state have been described after excessive alcohol consumption,40 drug abuse,51 and extreme emotional and physical stress.52 A noteworthy observation which was made, was that, many patients have tested MHS on in vitro contracture testing after an exercise-induced MH-like episode.53

Clinical presentation

Clinical symptoms of MH are highly variable, and range from abortive courses with mild or moderate symptoms to fulminant MH crises with severe skeletal muscle hypermetabolism and rhabdomyolysis. Excessive CO₂ production presenting with an increase in end tidal CO₂ concentration or hyperventilation while breathing spontaneously is a sensitive and specific early sign of imminent MH. An abrupt rise in end tidal CO₂ may occur simultaneously with administration of succinylcholine.53,54 Further early symptoms of an MH crisis may include tachycardia, supraventricular or ventricular arrhythmia, and isolated masseter spasm or generalized muscular rigidity. 50–80% of patients develop arrhythmia or muscular reactions.53 Nonspecific sinus tachycardia might be misinterpreted as inadequate anesthesia, which often delays the diagnosis of MH. Distinctive cyanosis indicating increased oxygen consumption may occur later in the course of an MH episode. A rapid increase in temperature (to >38.8°C) is a relatively late sign. However, a rapid increase of >1°C in 15 minutes is diagnostically more relevant than the peak temperature.52,55 In some cases, there are no relevant changes in body temperature, particularly if adequate treatment is started early.56,57 Arterial blood gas analyses reveal a combination of respiratory and metabolic acidosis with negative base excess, lactemia, hypercapnia, and hypoxemia. Fulminant MH crisis usually presents with PaCO₂ values >60 mmHg and a base excess of >8 mVal/L. As the MH episode progresses, rhabdomyolysis leads to hyperkalemia, increased creatine phosphokinase, and myoglobinemia, and might result in acute renal failure. The end stage of a fulminant MH crisis is characterized by multiorgan failure and circulatory collapse (Table 1).57

Initial treatment

The prognosis of an MH crisis depends on how soon MH is suspected and how rapidly appropriate treatment is initiated. Administration of trigger agents must be stopped immediately and anesthesia should be continued using intravenous opioids, sedatives, and, if necessary, nondepolarizing muscle relaxants. The vaporizer used for administration of volatile anesthesia should be removed from the anesthesia machine and the patient hyperventilated with 100% oxygen at maximum fresh gas flow, increasing the minute volume by approximately 2–3-fold while aiming for an end tidal pCO₂ within normal limits.

Treatment includes immediate administration of dantrolene 2 mg/kg, which should be repeated every 5 minutes until the cardiac and respiratory systems are stabilized. Dantrolene, a hydantoin derivative, acts as a specific ryanodine receptor antagonist and inhibits release of calcium from the sarcoplasmic reticulum without improving its reuptake. Specific side effects are rare, but include prolonged breathing problems, tissue necrosis after accidental extravasal injection, nausea, vomiting, headache, and dizziness.58

One bottle for injection contains 20 mg of dantrolene that has to be dissolved in 60 mL aqua destillata. To administer 2 mg/kg to an 80 kg patient, 160 mg of dantrolene (eight injection bottles) are necessary. A pharmacologic study suggested estimating the dantrolene dose needed according to the amount needed to alleviate symptoms, eg, 5 mg/kg in 24 hours if 2.5–5 mg/kg was administered initially or 10 mg/kg in 24 hours if 7.5–10 mg/kg was administered initially. If no improvement of symptoms is achieved after cumulative administration of 20 mg/kg, a diagnosis of MH is doubtful and needs to be reconsidered (Table 2).57,59

Symptomatic treatment

Subsequent steps might be necessary to avoid further harm to the patient, and volume resuscitation and administration of vasopressors might be needed to stabilize hemodynamics. Repeated arterial blood gas analysis and monitoring of serum electrolyte, creatine phosphokinase, myoglobin, and

### Table 1 Clinical signs of malignant hyperthermia

| Early | Late |
|-------|------|
| Masseter spasm | Hyperthermia |
| Generalized muscular rigidity (50%–80%) | Rhabdomyolysis |
| Tachycardia (>80%) | Acute renal failure |
| Hypercapnia | Cardiac arrhythmia |
| Hypoxia | Hypotension |
| Combined metabolic-respiratory acidosis | Circulatory failure |
Symptomatic treatment

Possible differential diagnoses of acute malignant hyperthermia crisis

| Differential diagnoses of malignant hyperthermia |  |
|-----------------------------------------------|--|
| Inadequate depth of anesthesia |  |
| Sepsis |  |
| Insufficient ventilation or spontaneous breathing |  |
| Malfunction of anesthesia machine |  |
| Anaphylactic reaction |  |
| Pheochromocytoma |  |
| Thyroid crisis |  |
| Neuromuscular disease |  |
| \(CO_2\) increase due to laparoscopic procedure |  |
| Drug intoxication |  |
| Serotonin syndrome |  |
| Malignant neuroleptic syndrome |  |

Lactate levels are important when determining the success of therapy. Administration of sodium bicarbonate or Tris buffer might be necessary to treat metabolic acidosis if pH is <7.2. Forced diuresis using fluid and furosemide can help to prevent acute renal failure. Cardiac arrhythmias are often reversible after administration of dantrolene. However, in some cases, administration of amiodarone or beta-blockers is indicated to treat persistent tachyarrhythmia. Administration of calcium antagonists is contraindicated, because severe episodes of hyperkalemia have been reported in the context of dantrolene treatment. Hyperthermia should be treated by internal cooling with cold infusion fluids and external surface cooling with ice packs placed in the axillae and groin or specific cooling devices until body temperature reaches 38.5°C. Surgery should be terminated as soon as possible and the patient should be transferred to an intensive care unit for further monitoring and treatment (Table 3). Telephone hotlines specialized in MH counseling have been established in a number of countries, and a smartphone application (“MHAApp”) issued by the European Malignant Hyperthermia Group in cooperation with the North American Malignant Hyperthermia Group can be consulted to support the initial therapeutic management.1

**Table 2** Possible differential diagnoses of acute malignant hyperthermia crisis

**Table 3** Immediate causative and symptomatic treatment of acute malignant hyperthermia crisis

**Diagnosis of MH susceptibility**

Diagnostic testing for MH susceptibility can be indicated after an incident suspicious for MH in patients with nonspecific myopathy or persistently elevated serum creatine kinase and in families with history of MH. For about 30 years, the in vitro contracture test using halothane and caffeine has been the gold standard for determining susceptibility to MH independent of a clinical MH event. Following a surgical muscle biopsy, live muscle specimens are exposed to defined concentrations of halothane or caffeine. If developing contracture forces exceed given thresholds after exposure to halothane and/or caffeine, the patient is diagnosed to be MHS. Absence of development of significant contracture following exposure to these agents leads to a diagnosis of MHN. There are two regional variations of this laboratory test. The in vitro contracture test according to the European Malignant Hyperthermia Group and the caffeine halothane contracture test according to the North American Malignant Hyperthermia Group11 differ slightly in the concentration of substance applied to the tissue bath and in mode of application (incremental versus bolus). However, adequate sensitivity and specificity has been demonstrated for both approaches.60,61 The previous existing intermediate diagnosis of MH-equivocal that was given to patients in the event of a significant reaction either after halothane or caffeine according to the European protocol has been abandoned in the recent update of the European Malignant Hyperthermia Group and replaced by the classification MHS in combination with an “h” (MHSh) if contracture developed after halothane only and a “c” (MHSc) if contracture occurred after caffeine only. This measure led to further harmonization of the two protocols.

DNA analysis as an alternative to the invasive contracture test has been of increasing importance over the last decade.12,62 Only a small blood sample is required to screen for an RYR1 mutation. Molecular genetic testing is often used first line as a diagnostic tool, particularly in families with a known causative RYR1 mutation. At this time, a patient is diagnosed as MHS if one of the 31 known causative mutations is detected. However, the diagnostic classification of many RYR1 mutations remains difficult, because their pathophysiologic impact with regard to initiating an MH reaction is not yet clear. Therefore, an in vitro contracture
test is required to confirm or exclude MH susceptibility in the event of an unclassified RYR1 mutation or if RYR1 mutation is absent.

A number of studies have focused on the development of less invasive functional testing procedures for determining predisposition to MH, eg, monitoring of intramuscular lactate levels by microdialysis after locally limited trigger application in vivo or pharmacologic stimulation of B lymphocytes in vitro, given that RYR1 is also expressed on human B lymphocytes. Although the results have been promising, none of these methods has progressed beyond the experimental stage as yet.

In summary, in vitro contracture testing and molecular genetic testing are the two approved methods for diagnosing susceptibility to MH. Both procedures require specialized testing centers and are not suitable for use as screening methods unless there is immediate suspicion of predisposition to MH.

Anesthesia in patients predisposed to MH

Providing safe anesthesia for MHS patients involves knowing about previously diagnosed MH status or potential susceptibility to MH. Although patients who have undergone an in vitro contracture test or genetic testing will usually present the relevant documents without needing to be asked, specific questions about personal or family history of MH, any critical incidents during anesthesia, and any other relevant muscular pathologies need to be asked about in every pre-anesthetic interview. In the event of a patient with confirmed or suspected susceptibility to MH, it is crucial to avoid any contact with MH triggering substances, which include all volatile anesthetics and succinylcholine. Apart from that, no specific monitoring or treatment is required. Predisposition to MH alone is not a contraindication for day-case surgery. Dantrolene must be readily available at every facility where trigger substances are used. However, prophylactic administration of dantrolene is regarded as obsolete.

Specific preparation of the anesthetic machine is required in order to prevent the MHS patient being exposed to volatile anesthetics. The necessary procedures and decontamination times vary depending on construction and applied materials among the different manufacturers and generations of machines.54–64 Maintaining a high fresh gas flow (eg, 10 L per minute) throughout the procedure seems to be important for avoiding a rebound phenomenon.54–66 Activated charcoal filters inserted into the breathing circuit can accelerate the purging procedure and might be valuable when preparing a machine for trigger-free anesthesia and for use in an acute MH crisis.66 Given that specific recommendations are lacking for many of the machines currently in use and that there is no clear-cut threshold for a residual concentration that is safe in terms of not triggering an MH crisis, an option could be to provide a specific machine within the department that has never been contaminated with volatile agents.69

Conclusion

Because of the variable clinical presentation of MH, ranging from abortive courses with only mild or moderate symptoms to fulminate MH crises, patient survival depends on early recognition of symptoms of MH and prompt action on the part of the attending anesthesiologist. In clinics that use known MH-triggering agents for induction and maintenance of general anesthesia, dantrolene must be available for immediate treatment and to reduce the risk of serious harm to the patient in the event of an episode of MH. After a suspected MH event, the patient should be referred to an MH center for further counseling.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Bandschapp O, Girard T. Malignant hyperthermia. Swiss Med Wkly. 2012;142:w13652.
2. Brewer G. Heat-stroke as a post-operative complication. J Am Med Assoc. 1900;35:1685.
3. Gibson C, Tuttle J. Heat stroke as a post-operative complication. Med News (NY). 1900;77:883–884.
4. Denborough MA, Forster JF, Lovell RR, Mapleton PA, Villiers JD. Anaesthetic deaths in a family. Br J Anaesth. 1962;34:395–396.
5. Harrison GG. Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. Br J Anaesth. 1975;47:62–65.
6. Britt BA, Kalow W. Malignant hyperthermia: a statistical review. Can Anaesth Soc J. 1970;17:293–315.
7. Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis. 2007;2:21.
8. Kalow W, Britt BA, Terreau ME, Haist C. Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet. 1970;2:895–898.
9. Ellis FR, Harriman DG, Keaney NP, Kyei-Mensah K, Tyrrell JH. Halothane-induced muscle contracture as a cause of hyperpyrexia. Br J Anaesth. 1971;43:721–722.
10. [No authors listed]. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group. Br J Anaesth. 1984;56:1267–1269.
11. Larach MG. Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group. Anest Analg. 1989;69:511–515.
12. Urwyler A, Deufel T, McCarthy T, West S, European Malignant Hyperthermia Group. Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br J Anaesth. 2001;86:283–287.
13. Larach MG, Gronert GA, Allen GC, Brandom BW, Lehman EB. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anest Analg. 2010;110:498–507.
14. Chamley D, Pollock NA, Stowell KM, Brown RL. Malignant hyperthermia in infancy and identification of novel RYR1 mutation. *Br J Anaesth*. 2000;84:500–504.

15. Brady JE, Sun LS, Rosenberg H, Li G. Prevalence of malignant hyperthermia due to anesthesia in New York State, 2001–2005. *Anesth Analg*. 2009;109:1162–1166.

16. Monnier N, Krivosic-Horber R, Payen JF, et al. Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. *Anesthesiology*. 2002;97:1067–1074.

17. Ørding H. Epidemiology of malignant hyperthermia. In: Schulte Br Am Esch J, Scholz J, Wappler F, editors. *Malignant Hyperthermia*. Lengerich, Germany: Pabst Science Publishers; 2000.

18. Schuster F, Johannsen S, Schneiderbauer D, Roewer N. Evaluation of suspected malignant hyperthermia events during anesthesia. *BMC Anesthesiol*. 2013;13:24.

19. Bundesinstitut für Arzneimittel und Medizinprodukte. Bekanntmachung der Erlösung fiktiver Arzneimittelzulassungen nach § 105 Abs. 3 Satz 1 des Arzneimittelgesetzes. Bundesanzeiger; 2001;11:61–62.

20. Hopkins PM. Malignant hyperthermia: pharmacology of triggering. *Br J Anaesth*. 2011;107:48–56.

21. Wedel DJ, Gammel SA, Milde JH, Iaizzo PA. Delayed onset of malignant hyperthermia induced by isoflurane and desflurane compared with halothane in susceptible swine. *Anesthesiology*. 1993;78:1138–1144.

22. DGAI. [Verwendung von Succinylcholin – Aktualisierte Stellungnahme der DGAI]. *Anästhes Intensivmed*. 2004;42:831. German.

23. Melzer W, Herrmann-Frank A, Luttgau HC. The role of Ca$^{2+}$ ions in excitation-contraction coupling of skeletal muscle fibres. *Biochim Biophys Acta*. 1995;1241:59–116.

24. Struk A, Lehmann-Horn F, Melzer W. Voltage-dependent calcium release in human malignant hyperthermia muscle fibers. *Biophys J*. 1998;75:2402–2410.

25. Yang T, Allen PD, Pessah IN, Lopez JR. Enhanced excitation-coupled calcium entry in myotubes is associated with expression of RyR1 malignant hyperthermia mutations. *J Biol Chem*. 2007;282:37471–37478.

26. Mickelsson JR, Gallant EM, Litterer LA, Johnson KM, Rempel WE, Louis CF. Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia. *J Biol Chem*. 1988;263:9310–9315.

27. Mickelsson JR, Louis CF. Malignant hyperthermia: excitation-contraction coupling. Ca$^{2+}$ release channel, and cell Ca$^{2+}$ regulation defects. *Physiol Rev*. 1996;76:537–592.

28. Litman RS, Rosenberg H. Malignant hyperthermia: update on susceptibility testing. *JAMA*. 2005;292:2918–2924.

29. Stathopoulos PB, Seo MD, Enomoto M, Amador FJ, Ishiyama N, Ikura M. Themes and variations in ER/SR calcium release channels: structure and function. *Physiology*. 2012;27:331–342.

30. Fill M, Copello JA. Ryanodine receptor calcium release channels. *Physiol Rev*. 2002;82:893–922.

31. Hamilton SL. Ryanodine receptors. *Cell Calcium*. 2005;38:253–260.

32. McCarthy TV, Healy JM, Jeffrson JJ, et al. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. *Nature*. 1990;343:562–564.

33. European Malignant Hyperthermia Group: Causative RyR1 mutations. 2013. Available from: http://www.emhg.org/genetics/mutations-in-ryr1/. Accessed March 12, 2014.

34. Rosenberg H. Mining for mutations in malignant hyperthermia. *Anesth Analg*. 2011;113:975–976.

35. Broman M, Heinecke K, Isander G, et al. Screening of the ryanodine 1 gene for malignant hyperthermia causative mutations by high resolution melt curve analysis. *Anesth Analg*. 2011;113:1120–1128.

36. Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P. Mutations in RYR1 in malignant hyperthermia and central core disease. *Hum Mutat*. 2006;27:977–989.

37. Samboukhin N, Holley H, Muldoon S, et al. Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the north american population. *Anesthesiology*. 2005;102:515–521.

38. Bramow BW. Genetics of malignant hyperthermia. *ScientificWorldJournal*. 2006;6:1722–1730.

39. Monnier N, Procaccio V, Stieglitz P, Lunardi J. Malignant hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. *Am J Hum Genet*. 1997;60:1316–1325.

40. Marchant CL, Ellis FR, Halsall PJ, Hopkins PM, Robinson RL. Mutation analysis of two patients with hypokalemic periodic paralysis and suspected malignant hyperthermia. *Muscle Nerve*. 2004;30:114–117.

41. Kunst G, Graf BM, Schreiner R, Martin E, Fink RH. Differential effects of sevoflurane, isoflurane, and halothane on Ca$^{2+}$ release from the sarcoplasmic reticulum of skeletal muscle. *Anesthesiology*. 1999;91:179–186.

42. McGrath CJ, Rempel WE, Jessen CR, Addis PB, Crimi AJ. Malignant hyperthermia-triggering liability of selected inhalant anesthetics in swine. *Am J Vet Res*. 1981;42:604–607.

43. Gronert GA, Milde JH. Hyperbaric nitrous oxide and malignant hyperpyrexia. *Br J Anaesth*. 1981;53:1238.

44. Froeba G, Marx T, Pazhur J, et al. Xenon does not trigger malignant hyperthermia in susceptible swine. *Anesthesiology*. 1999;91:1047–1052.

45. Baur CP, Klingler W, Jurkat-Rott K, et al. Xenon does not induce contracture in human malignant hyperthermia muscle. *Br J Anaesth*. 2000;85:712–716.

46. Riazi S, Larach MG, Hu C, Wijeyusundera D, Massey C, Kraeva N. Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands. *Anesth Analg*. 2014;118:381–387.

47. Johannsen S, Roewer N, Schuster F. Ondansetron-induced muscular contractures in malignant hyperthermia-susceptible individuals. *Anesth Analg*. 2012;115:925–928.

48. Capaccione JF, Muldoon SM. The relationship between exertional heat illness, exertional rhabdomyolysis, and malignant hyperthermia. *Anesth Analg*. 2009;109:1069–1069.

49. Wappler F. Anesthesia for patients with a history of malignant hyperthermia. *Curr Opin Anaesthesiol*. 2010;23:417–422.

50. Loghmanee F, Tobak M. Fatal malignant hyperthermia associated with recreational cocaine and ethanol abuse. *Am J Forensic Med Pathol*. 1986;7:246–248.

51. Merigian KS, Roberts JR. Cocaine intoxication: hyperpyrexia, rhabdomyolysis and acute renal failure. *J Toxicol Clin Toxicol*. 1987;25:135–148.

52. Wappler F, Fiege M, Steinfath M, et al. Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis. *Anesthesiology*. 2001;94:95–100.

53. Wappler F. Malignant hyperthermia. *Eur J Anaesthesiol*. 2001;18:632–652.

54. Tautz TJ, Urvyler A, Antognini JF, Riou B. Case scenario: increased end-tidal carbon dioxide: a diagnostic dilemma. *Anesthesiology*. 2010;112:440–446.

55. Larach MG, Localio AR, Allen GC, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. *Anesthesiology*. 1994;80:771–779.

56. Ali SZ, Taguchi A, Rosenberg H. Malignant hyperthermia. *Best Pract Res Clin Anaesthesiol*. 2003;17:519–533.

57. Glahn KP, Ellis FR, Halsall PJ, et al. Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group. *Br J Anaesth*. 2010;105:417–420.

58. Schuster F, Muller-Reibl CR. [Malignant hyperthermia – diagnostics, treatment and anaesthetic management]. *Anesthesiol Intensivmed Notfallmed Schmerzther.* 2009;44:758–763. German.

59. Podranski T, Bouillon T, Schumacher PM, Taguchi A, Sessler DI, Kurz A. Compartmental pharmacokinetics of dantrolene in adults: do malignant hyperthermia association dosing guidelines work? *Anesth Analg*. 2005;101:1695–1699.
60. Sei Y, Brandom BW, Bina S, et al. Patients with malignant hyperthermia demonstrate an altered calcium control mechanism in B lymphocytes. *Anesthesiology*. 2002;97:1052–1058.

61. Allen GC, Larach MG, Kunselman AR. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS. *Anesthesiology*. 1998;88:579–588.

62. Gunter C. Quantitative genetics. *Nature*. 2008;456:719.

63. Schuster F, Metterlein T, Negele S, et al. An in-vivo metabolic test for detecting malignant hyperthermia susceptibility in humans: a pilot study. *Anesth Analg*. 2008;107:909–914.

64. Kim TW, Nemergut ME. Preparation of modern anesthesia workstations for malignant hyperthermia-susceptible patients: a review of past and present practice. *Anesthesiology*. 2011;114:205–212.

65. Prinzhausen H, Crawford MW, O’Rourke J, Petroz GC. Preparation of the Drager Primus anesthetic machine for malignant hyperthermia-susceptible patients. *Can J Anaesth*. 2006;53:885–890.

66. Crawford MW, Prinzhausen H, Petroz GC. Accelerating the washout of inhalational anesthetics from the Drager Primus anesthetic workstation: effect of exchangeable internal components. *Anesthesiology*. 2007;106:289–294.

67. Shanahan H, O’Donoghue R, O’Kelly P, Synnott A, O’Rourke J. Preparation of the Drager Fabius CE and Drager Zeus anaesthetic machines for patients susceptible to malignant hyperthermia. *Eur J Anaesthesiol*. 2012;29:229–234.

68. Kim TW, Tham RQ. Washout times of desflurane, sevoflurane and isoflurane from the GE healthcare Aisys® and Avance® Carestation® and Aestiva® anesthesia system. *Paediatr Anaesth*. 2013;23:1124–1130.

69. Birgenheier N, Stoker R, Westenskow D, Orr J. Activated charcoal effectively removes inhaled anesthetics from modern anesthesia machines. *Anesth Analg*. 2011;112:1363–1370.

70. Martin JW, Welliver MD. Activated charcoal adsorption of volatile anesthetic agents for anesthesia machine preparation of malignant hyperthermia susceptible patients. *AANA J*. 2013;81:169–171.